PTH and chronic kidney disease: By conducting this study, the authors have attempted to show that SHPT can be managed satisfyingly enough, achieving acceptable PTH levels in patients with end-stage CKD by using new second generation calcimimetic agents, while tampering with patient compliance and minimizing side effects deriving from first generation calcimimetic agents.